Glumetinib is primarily used as a targeted anticancer agent, specifically developed for the treatment of non-small cell lung cancer (NSCLC) with EGFR mutations, including T790M resistance mutations. It functions as a irreversible inhibitor of EGFR tyrosine kinase, effectively blocking signaling pathways that drive tumor cell proliferation and survival. Due to its high selectivity and potency against mutant EGFR forms, glumetinib shows strong antitumor activity in patients who have developed resistance to first- or second-generation EGFR inhibitors. It is being evaluated in clinical trials to assess its efficacy, safety, and optimal dosing in advanced or metastatic NSCLC. Its ability to penetrate the blood-brain barrier also makes it a promising candidate for treating brain metastases associated with lung cancer.